Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pediatric study of KAF156 + lumefantrine-SDF versus Coartem for uncomplicated Plasmodium falciparum malaria
2021-003583-27Phase 2
- Sponsor
- Novartis
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Malaria and Falciparum malaria (PF) comparing KAF156 + lumefantrine-SDF with Coartem comparator (2 arms). Primary endpoint: PCR-corrected adequate clinical and parasitological response at Day 29.
02
Drugs
ganaplacidelumefantrine
03
Conditions
MalariaFalciparum malaria (PF)
Beyond the preview
Go deeper on 2021-003583-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003583-27.